ALK(SZ:002940) Xin Lang Zheng Quan·2025-09-01 03:19Company Overview - Angli康 is a pharmaceutical company based in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company specializes in the research, production, and sales of chemical raw materials and formulations [1]. - The main business revenue composition includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Stock Performance - As of September 1, Angli康's stock price increased by 2.00% to 50.41 CNY per share, with a trading volume of 215 million CNY and a turnover rate of 2.34%, resulting in a total market capitalization of 10.169 billion CNY [1]. - Year-to-date, Angli康's stock price has risen by 286.05%, but it has seen a decline of 9.37% over the last five trading days and 22.09% over the last 20 days. In the last 60 days, the stock price increased by 134.92% [1]. Financial Performance - For the first half of 2025, Angli康 reported a revenue of 724 million CNY, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.925 million CNY, down 3.19% year-on-year [2]. - Since its A-share listing, Angli康 has distributed a total of 341 million CNY in dividends, with 108 million CNY distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, Angli康 had 18,500 shareholders, an increase of 50.49% from the previous period. The average number of circulating shares per person decreased by 33.55% to 10,037 shares [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.4373 million shares, and Guangfa Technology Innovation Mixed A, holding 6.1606 million shares [3].